文献速递炎症性肠病

特定碳水化合物饮食与地中海饮食在轻中度克罗恩病成人中的随机对照试验

A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
PubMed 文献 · Gastroenterology · 2021-05-27

本研究将194例轻中度症状的克罗恩病成人随机分配至地中海饮食(MD)或特定碳水化合物饮食(SCD)组,干预12周。SCD并不优于MD,且CRP应答罕见;考虑到MD更易遵循且具有其他健康益处,对多数轻中度症状克罗恩病患者MD可能优于SCD。

要点

  • SCD在症状缓解、粪便钙卫蛋白应答和CRP应答方面均不优于地中海饮食。

核心结论

  • 特定碳水化合物饮食(SCD)在实现症状缓解、粪便钙卫蛋白应答和C反应蛋白应答方面不优于地中海饮食(MD)。
  • C反应蛋白应答罕见,且考虑到MD更易遵循及其他健康益处,对多数轻中度症状的克罗恩病患者MD可能优于SCD。

研究设计与样本

  • 随机对照试验,将轻中度症状的克罗恩病成人按1:1随机分配至MD或SCD组,干预12周;前6周提供按指定饮食准备的食物和零食,之后指导独立遵循饮食。
  • 共随机194例患者,191例纳入有效性分析。

关键数值与推荐

  • 主要结局为第6周症状缓解。
  • 粪便钙卫蛋白应答定义为基线FC>250 μg/g者中FC<250 μg/g且较基线下降>50%。
  • C反应蛋白应答定义为基线高敏CRP>5 mg/L者中高敏CRP<5 mg/L且较基线下降>50%。

临床怎么用

  • 对轻中度症状的克罗恩病成人,地中海饮食可作为优先于特定碳水化合物饮食的饮食选择。
  • 不应期望特定碳水化合物饮食在症状缓解或炎症标志物应答上优于地中海饮食。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This study compared the effectiveness of the Specific Carbohydrate Diet (SCD) to the Mediterranean diet (MD) as treatment for Crohn's disease (CD) with mild to moderate symptoms. METHODS: Adult patients with CD and with mild-to-moderate symptoms were randomly assigned 1:1 to consume the MD or SCD for 12 weeks. For the first 6 weeks, participants received prepared meals and snacks according to their assigned diet. After 6 weeks, participants were instructed to follow the diet independently. The primary outcome was symptomatic remission at week 6. Key secondary outcomes at week 6 included fecal calprotectin (FC) response (FC <250 μg/g and reduction by >50% among those with baseline FC >250 μg/g) and C-reactive protein (CRP) response (high-sensitivity CRP <5 mg/L and >50% reduction from baseline among those with high-sensitivity CRP >5 mg/L). RESULTS: The study randomized 194 patients, and 191 were included in the efficacy analyses. The percentage of participants who achieved symptomatic remission at week 6 was not superior with the SCD (SCD, 46.5%; MD, 43.5%; P = .77). FC response was achieved in 8 of 23 participants (34.8%) with the SCD and in 4 of 13 participants (30.8%) with the MD (P = .83). CRP response was achieved in 2 of 37 participants (5.4%) with the SCD and in 1 of 28 participants (3.6%) with the MD (P = .68). CONCLUSIONS: The SCD was not superior to the MD to achieve symptomatic remission, FC response, and CRP response. CRP response was uncommon. Given these results, the greater ease of following the MD and other health benefits associated with the MD, the MD may be preferred to the SCD for most patients with CD with mild to moderate symptoms. ClinicalTrials.gov Identifier: NCT03058679.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Lewis JD, Sandler RS, Brotherton C, et al. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. Gastroenterology. 2021. PMID: 34052278. doi:10.1053/j.gastro.2021.05.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。